Glucose metabolism and pathological findings in uveal melanoma preliminary results

Nuclear Medicine Communications

Volumn 17, Issue 12, 1996, Pages 1052-1056

  Modorati, G ^a   Trabucchi, G ^a   Brancato, Rosario ^a   Lucignani, G ^a   Landoni, C ^a   Fazio, F ^a   Freschi, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; UVEA MELANOMA;

EID: 0030448019     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199612000-00009     Document Type: Article

References (29)

1. Warburg O. Uber den stoffzechsel der tumoren. Berlin: Springer, 1926.
2. Weinhouse S. The Warburg hypothesis fifty years later. Z Krebsforsch 1976; 87: 115-126.
3. Fishman AJ, Alpert NM. FDG-PET in oncology: There is more to it than looking at pictures. J Nucl Med 1993; 34: 6-11.
4. Di Chiro G. Brain imaging of glucose utilization in cerebral tumors. In: Sokoloff L, ed. Brain imaging and brain function. New York: Raven Press, 1985.
5. Di Chiro G, Fulham MJ. Virchow’s shackles: Can PET-FDG challenge tumor histology? AJNR 1983; 14: 524-527.
6. Minn H, Joensuu H, Ahonen A et al. Fluorodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988; 61: 1776-1781.
7. Di Chiro G, DeLaPaz RL, Brooks R et al Glucose utilization of cerebral gliomas measured by 18-F-fluoro-deoxyglucose and positron emission tomography. Neurology 1982: 32: 1323-1329.
8. Patronas NJ, Di Chiro G, Kufta C et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985; 62: 816-822.
9. Tyler J, Diksic M, Villemure JG et al. Metabolic and haemo-dynamic evaluation of gliomas using positron-emission tomography. J Nucl Med 1987; 28: 1123-1133.
10. Alavi JB, Alavi A, Chawluk J et al. Positron emission tomography in patients with glioma: A predictor of prognosis. Cancer 1988; 62: 1074-1078.
11. Scislowski PWD, Slominski A, Bomirski A. Biochemical characterization of three hamster melanoma variants. II: Glycolysis and oxygen consumption. Int J Biochem 1984; 3: 327-331.
12. Brancato R, Lucignani G, Modorati G et al. Metabolic imaging of uveal melanoma using positron emission tomography. Arch Ophthalmol 1990; 108: 326-327.
13. Modorati G, Brancato R, Striano G et al. Positron emission tomography (PET) for metabolic imaging of choroidal melanoma. Invest Ophthal Vis Sci 1990; 31: 588.
14. Lucignani G, Paganelli G, Modorati G et al. MRI, antibody-guided scintigraphy, and glucose metabolism in uveal melanoma. J Comp Assist Tomog 1992; 16: 77-83.
15. Shields JA, Shields CL, Donoso LA. Current management of posterior uveal melanoma. Surv Ophthalm NI 1991; 36: 161-295.
16. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 1983; 101: 1894-1899.
17. Onda K, Davis RL, Shibuya M, Wilson CB, Hoshino T. Correlation between the bromodeoxyuridine labeling index and MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 1994; 74: 1921-1926.
18. Kubota K, Kubota R, Yamada S. FDG accumulation in tumor tissue. J Nucl Med 1993; 34: 419-421.
19. Minn H, Soini I. [18F]-Fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur J Nucl Med 1989; 15: 61-66.
20. Minn H, Paul R, Ahonen A et al. Evaluation of treatment response to radiotherapy in head and neck cancer with (18F)-Fluorodeoxyglucose. J Nucl Med 1988; 21: 1521-1525.
21. Patronas NJ, Di Chiro G, Brooks RA et al. Work in progress: [18Fl-Fluorodeoxyglucose and emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982; 144: 885-889.
22. Yonekura, J, Benua RS, Brill AB et al. Increased accumulation of 2-deoxy-2-(18-F)fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med 1982; 23: 1133-1137.
23. Nolop KB, Rhodes CG, Brudin LH et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987: 60: 2682-2689.
24. Strauss LG, Conti P. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623-648.
25. Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ. Glucose utilization by intracranial meningiomas as index of tumor aggressivity and probability of recurrence: A PET study. Radiology 1987; 164: 521-526.
26. Chapman JD. The detection and measurement of hypoxic cells in solid tumors. Cancer 1984: 54: 2441-2449.
27. Moulder JE, Rockwell S. Hypoxic fraction of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 1984; 10: 695-712.
28. Harwood AR, Cummings BJ. Radiotherapy for malignant melanoma: A reappraisal. Cancer Treat Rev 1981; 8: 271-282.
29. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995: 365: 1625-1632.